General Automotive Co. (GNAU: OTC Pink Current) | MDCorp Executes LOI to Acquire European Distribution Business

OTC

MDCorp Executes LOI to Acquire European Distribution Business

Apr 21, 2017

OTC Disclosure News Service

Seattle, WA

0
0
1
596
3398
pamco
28
7
3987
14.0

Normal
0

false
false
false

EN-US
ZH-CN
X-NONE

<![CDATA[

]]>

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin:0in;
mso-para-margin-bottom:.0001pt;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:EN-US;}

For Immediate Release:

 

MDCorp
has executed an LOI to acquire 100% equity stake in
Terramed, Ltd., Intellemed Ltd., Neuraxon, Ltd. hereafter described as “European
Distribution Medical Systems” (EDMS).   The EMDS group shall upon successful
acquisition, if completed, become a wholly owned subsidiary of MDCorp.

 

EDMS
represents a trio of European Medical distribution companies headed by Mr.
Pantelis Stanitsas historically covering 6 countries in the European Union with
sales channels into the United Kingdom, Greece, Cyprus, Romania, Bulgaria, and
Kazakhstan.  Revenues currently in the
neighborhood of $3 million Euros are expected to expand with more capital
funding.  It is expected that our
cooperation and acquisition shall allow EDMS as a wholly owned subsidiary of
MDCorp to take advantage of new products and services layered across a growing
base of new branch offices.

 

EDMS
seeks to utilize over 15 years of local market expertise and funding from
MDCorp to open new branch offices and expand sales, layering more products and
services through existing and then new sales channels.

 

Inquiries:  mdc@mdcorp.com

 

Forward-Looking Statements

This press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions
of the Private Securities Litigation Reform Act of 1995, including but not
limited to, statements regarding the MDCorp’s position as a market leader,
acceleration of innovation and expansion of total addressable market
opportunity.  These forward-looking statements are made as of the date
they were first issued and were based on current expectations, estimates,
forecasts and projections as well as the beliefs and assumptions of
management. Words such as “expect,” “anticipate,”
“should,” “believe,” “hope,” “target,”
“project,” “goals,” “estimate,”
“potential,” “predict,” “may,” “will,”
“might,” “could,” “intend,” variations of these
terms or the negative of these terms and similar expressions are intended to
identify these forward-looking statements. Forward-looking statements are
subject to a number of risks and uncertainties, many of which involve factors
or circumstances that are beyond the MDCorp’s control.  MDCorp’s actual
results could differ materially from those stated or implied in forward-looking
statements due to a number of factors, including but not limited to (1) failure
to realize the estimated synergies or growth anticipated as a result of the
transactions or that such benefits may take longer to realize than expected,
(2) risks related to unanticipated costs of integration of European
Distribution Medical Systems by MDCorp, (3) the effect of the consummation
of the transactions on the ability of MDCorp to retain and hire key
personnel and maintain relationships with key business partners and customers,
and on MDCorp’s operating results and businesses generally, (4) adverse trends
in economic conditions generally or in the industries in which the MDCorp
operates, (5) adverse changes to, or interruptions in, relationships with third
parties unrelated to the merger, (6) MDCorp’s ability to compete effectively
and successfully and to add new products and services, (7) MDCorp’s ability to
successfully manage and integrate acquisitions, (8) the ability to attract new
customers and retain existing customers in the manner anticipated, (9)
unanticipated changes relating to competitive factors in the MDCorp’s
industries, and (10) any business interruptions in connection with MDCorp’s acquired
technology, sales or systems.  MDCorp is under no obligation, and
expressly disclaims any obligation, to update, alter, or otherwise revise any
forward-looking statements, whether written or oral, that may be made from time
to time, whether as a result of new information, future events, or
otherwise.  Persons reading this announcement are cautioned not to place
undue reliance on these forward-looking statements which speak only as of the
date hereof.

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply